Grant of Options under Long Term Incentive Plan

RNS Number : 9885G

Allergy Therapeutics PLC

25 November 2015

 



25 November 2015

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Grant of Options under Long Term Incentive Plan

Allergy Therapeutics plc confirms that certain performance conditions attaching to provisional awards ("Awards") made pursuant to the Company's Long Term Incentive Plan ("LTIP") for the three years ended 30 June 2015, details of which were announced on 19 December 2012, have been met. Consequently, Allergy Therapeutics has today granted certain of its directors nil cost options ("Options") over the Company's ordinary shares of 0.1 pence each ("Ordinary Shares") in replacement for the Awards made under the LTIP as follows:

Director	Number of Ordinary Shares over which Options granted	Total number of Ordinary Shares over which Options granted	Total remaining number of Ordinary Shares provisionally  awarded under LTIPs
Manuel Llobet, Chief Executive Officer	624,024	624,024	2,595,000
Ian Postlethwaite, Finance Director	312,012	475,512	1,297,500

The Options have been granted in accordance with the LTIP rules and can be exercisable at nil cost between 25 December 2015 and 25 December 2018.

For further information:

Allergy Therapeutics	[phone]
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
Panmure Gordon	[phone]
Freddy Crossley / Peter Steel / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
FTI Consulting	[phone]
Simon Conway
Victoria Foster Mitchell

Note to editors:

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination.  It has a growing business achieving revenue in the last financial year of £43 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.

 

END

 

 

RDSZMMZMNKRGKZM